<DOC>
	<DOC>NCT00551577</DOC>
	<brief_summary>The purpose of this study is to evaluate response to neoadjuvant chemotherapy by imaging and observation of anatomical and biological indicators (i.e. ascites or continuous measurement of tumor marker CA 125). Furthermore the optimal number of preoperative administered cycles of combination chemotherapy with carboplatin and docetaxel should be determined.</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Patients With Advanced Ovarian Cancer-Prospective, Randomized Phase II Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>histological confirmed ovarian neoplasm Figo stage IIIC (2cm extrapelvic disease) or Figo IV more than 500 ml ascites volume (measured by sonography) age &gt; 18 years old ECOG &lt;= 2 adequate hepatological, renal and haematological function informed consent concomitant or previous malignant diseases debulking procedures on initial surgical approach existing peripheral sensoric neuropathy &gt;= grade 2 acute infections mental disorders, cerebral metastasis bowel obstruction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Ovarian neoplasms,</keyword>
	<keyword>Neoadjuvant Therapy,</keyword>
	<keyword>Docetaxel,</keyword>
	<keyword>Neoplasm, Residual</keyword>
</DOC>